Sort
82,697 grants matching “vaccine development”
Task 12/D20 Testing of Antibiotics Against Tularemia
$2,783,320Mary Bruce · Battelle Memorial Institute · N01 · FY2009 · AI
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
$2,782,255Carl H. June · University Of Pennsylvania · P01 · FY2023 · CA
Vaccine Induced Immunity in the Young and Aged
$2,782,096Rafi Ahmed · Emory University · U19 · FY2021 · AI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers
$2,781,188William C Olson · Progenics Pharmaceuticals, Inc. · P01 · FY2010 · AI
Optimizing the Immunogenicity of MVA-Based AIDS Vaccines
$2,780,254Mark B. Feinberg · Emory University · U19 · FY2006 · AI
Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections
$2,779,955Mariette Barbier · West Virginia University · R01 · FY2025 · AI
Immune Modulation After Allogeneic HCT
$2,779,234Robert Jon Soiffer · Dana-Farber Cancer Inst · P01 · FY2019 · CA
SPORE IN BREAST CANCER
$2,778,284Johns Hopkins University · P50 · FY2001 · CA
Hematopoietic Cell Transplantation for Hematologic Malignancies
$2,776,839Stephen J Forma · Beckman Research Institute/City Of Hope · P01 · FY2007 · CA
Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax
$2,776,772Kenneth Mark Coggeshall · Oklahoma Medical Research Foundation · U19 · FY2012 · AI
Research Project 2: Therapeutic Human Monoclonal Antibody Treatments for Filoviruses
$2,775,679James E Crowe · University Of Texas Med Br Galveston · U19 · FY2020 · AI
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$2,775,051Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Discovery of Novel Broad-Spectrum Coronavirus Mpro Inhibitors
$2,770,981Julien Papillon · University Of Texas Med Br Galveston · U19 · FY2022 · AI
Core A: Administrative
$2,769,693Lynda Stuart · University Of Washington · U19 · FY2024 · AI
NCI-Frederick Support and Technical Services
$2,769,548Douglas R. Lowy · Office Of The Director, Nci · ZIC · FY2019 · CA
Pulmonary responses to Bioweapon Category A Pathogens
$2,769,297Clifford Rick Lyons · University Of New Mexico · P01 · FY2008 · AI
Resources and Workforce Development for the Regional Biocontainment Laboratories
$2,769,099Herman F. Staats · Duke University · UC7 · FY2025 · AI
University of Pittsburgh Clinical Trials Unit
$2,768,591John W Mellors · University Of Pittsburgh At Pittsburgh · U01 · FY2010 · AI
Innate and Adaptive Immunity in Experimental and Human Gonoccocal Infection
$2,768,529Peter A. Rice · Univ Of Massachusetts Med Sch Worcester · U19 · FY2012 · AI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders
$2,767,364Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2014 · HL
Characterizing pediatric genomes through an optimized sequencing approach
$2,765,194Shawn E Levy · Hudson-Alpha Institute For Biotechnology · U24 · FY2017 · HD
NIAID-VRC-Research, Development, and Production to Support Ebola Bispecific Antibody Development
$2,765,029Chris Case · Leidos Biomedical Research, Inc. · N01 · FY2022 · AI
Research Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State University
$2,763,138Karen Marie Dobos · Colorado State University · UC7 · FY2025 · AI
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$2,762,918Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Development of a Vaccine for HIV-AIDS: Humoral Immunity
$2,762,142Marjorie Guroff · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA